Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:BHST NASDAQ:GANX NASDAQ:PLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.76+0.3%$0.93$0.53▼$1.45$19.21M0.66131,280 shs34,284 shsBHSTBioHarvest Sciences$3.86$4.18$3.57▼$12.80$75.73M0.735,189 shs20,427 shsGANXGain Therapeutics$1.95$1.87$1.41▼$4.34$83.17M0.16595,508 shs868,684 shsPLRXPliant Therapeutics$1.26$1.25$1.09▼$1.95$78.02M1.2419,755 shs314,921 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%-2.34%-17.05%-28.40%+31.77%BHSTBioHarvest Sciences0.00%0.00%-8.31%-14.41%-38.44%GANXGain Therapeutics0.00%+9.55%+3.17%-28.04%+9.86%PLRXPliant Therapeutics0.00%+4.13%+3.28%-0.79%-8.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.76+0.3%$0.93$0.53▼$1.45$19.21M0.66131,280 shs34,284 shsBHSTBioHarvest Sciences$3.86$4.18$3.57▼$12.80$75.73M0.735,189 shs20,427 shsGANXGain Therapeutics$1.95$1.87$1.41▼$4.34$83.17M0.16595,508 shs868,684 shsPLRXPliant Therapeutics$1.26$1.25$1.09▼$1.95$78.02M1.2419,755 shs314,921 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%-2.34%-17.05%-28.40%+31.77%BHSTBioHarvest Sciences0.00%0.00%-8.31%-14.41%-38.44%GANXGain Therapeutics0.00%+9.55%+3.17%-28.04%+9.86%PLRXPliant Therapeutics0.00%+4.13%+3.28%-0.79%-8.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00BuyN/AN/ABHSTBioHarvest Sciences 2.00Hold$10.00159.07% UpsideGANXGain Therapeutics 2.67Moderate Buy$8.50335.90% UpsidePLRXPliant Therapeutics 1.80Reduce$3.00138.10% UpsideCurrent Analyst Ratings BreakdownLatest AEON, GANX, BHST, and PLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026GANXGain Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/27/2026AEONAEON Biopharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/12/2026GANXGain Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/21/2026PLRXPliant Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026GANXGain Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/13/2026PLRXPliant Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$4.00 ➝ $3.003/12/2026PLRXPliant Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$4.00 ➝ $3.00(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/ABHSTBioHarvest Sciences$34.51M2.19N/AN/A$1.30 per share2.97GANXGain Therapeutics$50K1,663.35N/AN/A$0.48 per share4.06PLRXPliant Therapeutics$1.58M49.38N/AN/A$2.95 per share0.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M-$5.004.22N/AN/AN/AN/A-994.63%8/11/2026 (Estimated)BHSTBioHarvest Sciences-$11.14M-$0.59N/AN/AN/A-32.54%-76.03%-25.30%8/10/2026 (Estimated)GANXGain Therapeutics-$20.16M-$0.58N/AN/AN/AN/A-201.44%-136.24%8/11/2026 (Estimated)PLRXPliant Therapeutics-$149.34M-$1.84N/AN/AN/AN/A-58.11%-44.37%8/6/2026 (Estimated)Latest AEON, GANX, BHST, and PLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026BHSTBioHarvest Sciences-$0.13-$0.11+$0.02-$0.11$8.50 million$8.51 million5/11/2026Q1 2026GANXGain Therapeutics-$0.13-$0.13N/A-$0.13$0.03 millionN/A5/11/2026Q1 2026PLRXPliant Therapeutics-$0.36-$0.32+$0.04-$0.32N/AN/A4/1/2026Q4 2025BHSTBioHarvest Sciences-$0.11-$0.10+$0.01-$0.10$9.24 million$9.07 million3/26/2026Q4 2025GANXGain Therapeutics-$0.14-$0.11+$0.03-$0.11$0.03 millionN/A3/11/2026Q4 2025PLRXPliant Therapeutics-$0.44-$0.35+$0.09-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/ABHSTBioHarvest SciencesN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22BHSTBioHarvest Sciences0.032.962.44GANXGain Therapeutics0.024.694.69PLRXPliant TherapeuticsN/A16.8916.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%BHSTBioHarvest SciencesN/AGANXGain Therapeutics11.97%PLRXPliant Therapeutics97.30%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma9.40%BHSTBioHarvest SciencesN/AGANXGain Therapeutics4.15%PLRXPliant Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma525.30 million74.37 millionNot OptionableBHSTBioHarvest SciencesN/A19.62 millionN/AN/AGANXGain Therapeutics2042.65 million40.88 millionOptionablePLRXPliant Therapeutics9061.92 million57.96 millionOptionableAEON, GANX, BHST, and PLRX HeadlinesRecent News About These CompaniesPliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 22, 2026 | seekingalpha.comPliant Therapeutics Announces Enrollment in Phase 1b Trial of PLN-101095 for ICI-Refractory Solid Tumors at ASCO 2026May 21, 2026 | quiverquant.comQPliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual MeetingMay 21, 2026 | globenewswire.comPliant Therapeutics Stock Short Interest Report | NASDAQ:PLRX | BenzingaMay 17, 2026 | benzinga.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 11, 2026 | finance.yahoo.comPliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wall Street ZenMay 11, 2026 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of "Reduce" from AnalystsMay 10, 2026 | marketbeat.comPliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on MondayMay 6, 2026 | marketbeat.comPliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceMay 6, 2026 | globenewswire.comBML Capital Management LLC Buys Shares of 1,546,137 Pliant Therapeutics, Inc. $PLRXMay 6, 2026 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street ZenMay 3, 2026 | marketbeat.comPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsApril 30, 2026 | markets.businessinsider.comPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsApril 30, 2026 | globenewswire.comPliant Therapeutics Presents Promising Phase 1b Trial Data for PLN-101095 in Combination with Pembrolizumab for ICI-Refractory Advanced Tumors at AACR 2026April 18, 2026 | quiverquant.comQPliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual MeetingApril 18, 2026 | globenewswire.comPliant Therapeutics Launches New $50 Million ATM ProgramMarch 30, 2026 | tipranks.comPliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72March 27, 2026 | msn.comPliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in ...March 18, 2026 | bakersfield.comBPliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual MeetingMarch 18, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pliant Therapeutics (PLRX) and Cytokinetics (CYTK)March 14, 2026 | theglobeandmail.comPliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial ResultsMarch 12, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEON, GANX, BHST, and PLRX Company DescriptionsAEON Biopharma NASDAQ:AEON$0.76 +0.00 (+0.30%) Closing price 05/29/2026 03:55 PM EasternExtended Trading$0.74 -0.02 (-2.77%) As of 08:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.BioHarvest Sciences NASDAQ:BHST$3.86 0.00 (0.00%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$3.87 +0.01 (+0.26%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Gain Therapeutics NASDAQ:GANX$1.95 0.00 (0.00%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.99 +0.04 (+2.00%) As of 09:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Pliant Therapeutics NASDAQ:PLRX$1.26 0.00 (0.00%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.24 -0.02 (-1.98%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Alphabet Bets on Hardware With Googlebook and AI Glasses Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
